GHO Capital

Day-to-day decisions sit with the three managing partners — Alan MacKay, Andrea Ponti and Mike Mortimer — all of whom worked together in 3i's healthcare team before founding GHO in 2014. The firm operates a flat investment committee where all three carry equal weight, supported by sector-specific partners covering pharma services, medtech and healthcare providers. No single partner can unilaterally commit capital above a pre-agreed threshold, per the firm's public governance materials.

GHO's mandate is exclusively European, but its portfolio companies often generate substantial revenue in North America and Asia. The firm invests in businesses headquartered in Western Europe — principally the UK, Ireland, DACH, Nordics and Benelux — and then uses its capital to accelerate international expansion. It has not opened non-European offices and does not do direct investments in North American or Asian target companies.

GHO actively offers co-investment rights to its limited partners on larger transactions, particularly those exceeding €200 million in enterprise value, per LP communications. The firm has not historically syndicated co-invest to non-LP outside capital, preferring to deepen relationships with existing institutional backers rather than broaden the investor base.

GHO relies on a proprietary origination model rather than auction processes. The operating partner network — composed of former pharma executives, hospital CEOs and regulatory experts — identifies founder-owned businesses approaching succession before they formally come to market. The firm then negotiates bilaterally over extended periods, often 12–18 months, structuring transactions where the founder remains a minority shareholder during a defined earn-out period.

GHO avoids pure-play health tech and software-as-a-medical-device businesses where valuations are driven by recurring-revenue multiples rather than clinical outcomes — the firm has publicly stated it invests in 'healthcare, not health tech.' It also avoids public-to-private transactions in regulated payor markets like the NHS where political risk is difficult to underwrite, and stays away from Phase I biotech assets that require binary FDA approval bets.

No. GHO maintains a single-product structure — control buyouts in its flagship closed-end funds. It has not launched complementary credit strategies, continuation vehicles, or early-stage healthcare venture funds, which distinguishes it from mid-market peers like Archimed or Gilde Healthcare that operate multi-strategy platforms.

GHO does not publicly disclose fund-level IRRs or MOICs. Fund I has fully exited several assets, per the firm's investor letters, but discrete performance data is limited to LP reports. The €2.3 billion close of Fund III in 2023 — triple the size of Fund II — serves as the strongest public signal of re-up rates and LP satisfaction.